CDC-like Kinase (CLK) Inhibitors Market Expected to Witness Significant Growth Through 2036, Driven by Advancing RNA Splicing-Targeted Therapies and Expanding Oncology Applications | DelveInsight

The CDC-like Kinase (CLK) Inhibitors market is expected to witness significant growth across the Seven Major Markets (7MM) during the forecast period (2022-2036). Market growth is anticipated to be driven by increasing research into RNA splicing-targeted therapeutics, expanding applications across hematological malignancies and solid tumors, growing understanding of CLK-mediated disease biology, and the advancement of several promising CLK inhibitor candidates through clinical development. Although no CLK-targeted therapies have yet received regulatory approval, continuous innovation in precision oncology and RNA splicing modulation is expected to unlock substantial commercial opportunities.

DelveInsight's "CDC-like Kinase (CLK) Inhibitors - Target Population, Competitive Landscape, and Market Forecast-2036" report provides a comprehensive assessment of target patient populations, emerging therapies, competitive landscape, market trends, pricing analysis, therapy uptake, reimbursement scenario, technology assessment, and market forecasts across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan (7MM). The report further evaluates key opinion leader (KOL) perspectives, strategic collaborations, commercial opportunities, and market dynamics expected to shape the CLK Inhibitors market through 2036.

The report also delivers detailed insights into historical and forecasted market performance, target population analysis, indication-wise market forecasts, emerging therapy assessment, SWOT analysis, pricing dynamics, technology assessment, and the evolving competitive landscape to support strategic decision-making for pharmaceutical and biotechnology companies developing RNA splicing-targeted therapies.

To know more about the CDC-like Kinase (CLK) Inhibitors market, target population, and forecast, Click here:
https://www.delveinsight.com/sample-request/clk-inhibitors-market-forecast?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Takeaways from the CDC-like Kinase (CLK) Inhibitors Market Report
• The CDC-like Kinase (CLK) Inhibitors market is expected to expand significantly across the 7MM during the forecast period (2022-2036), supported by increasing investment in RNA splicing-targeted therapies, expanding oncology applications, and the advancement of multiple first-in-class clinical candidates.
• CLK inhibitors target the CLK1, CLK2, CLK3, and CLK4 isoforms, which regulate pre-mRNA splicing through serine/arginine-rich (SR) protein phosphorylation. Dysregulated RNA splicing is increasingly recognized as a critical driver of tumor progression across multiple cancers, making CLK inhibition an attractive therapeutic strategy.
• According to DelveInsight's analysis, approximately 44,000 incident cases of Acute Myeloid Leukemia (AML) were reported across the 7MM in 2025, representing one of the major target populations for emerging CLK inhibitors.
• Among the 7MM, the United States accounted for the highest number of AML cases in 2025, while additional target indications include Small Cell Lung Cancer (SCLC), Colorectal Cancer (CRC), Knee Osteoarthritis, and other selected diseases currently being evaluated for CLK inhibition.
• Promising pipeline therapies include Rogocekib (CTX-712) (Chordia Therapeutics), BH-30236 (BlossomHill Therapeutics), Lorecivivint (SM04690) (Biosplice Therapeutics), Cirtuvivint (SM08502) (Biosplice Therapeutics), and Emavusertib (CA-4948) (Curis), among others.
• In March 2026, BlossomHill Therapeutics announced that it would present new preclinical data supporting the continued advancement of BH-30236, an oral CLK inhibitor being developed for hematologic malignancies. Additionally, in January 2026, Chordia Therapeutics announced publication of the final peer-reviewed Phase I results of Rogocekib (CTX-712) in Blood Advances, while Biosplice Therapeutics submitted an NDA to the US FDA for Lorecivivint (SM04690) for knee osteoarthritis.

Key Factors Driving the CDC-like Kinase (CLK) Inhibitors Market

Growing Interest in RNA Splicing-Targeted Oncology
Increasing recognition of aberrant RNA splicing as a key mechanism driving cancer progression has accelerated development of CLK inhibitors capable of disrupting spliceosome-mediated tumor cell survival and proliferation.

Expanding Clinical Applications Across Multiple Indications
Current research and clinical development extend beyond hematological malignancies into solid tumors, including Small Cell Lung Cancer, Colorectal Cancer, and other malignancies, while exploratory studies continue investigating broader therapeutic applications.

Strong Emerging Pipeline
Several first-in-class and highly selective CLK inhibitors, including Rogocekib (CTX-712), BH-30236, Lorecivivint (SM04690), Cirtuvivint (SM08502), and Emavusertib (CA-4948), are progressing through clinical development and are expected to significantly strengthen the future competitive landscape.

Precision Oncology and Novel Mechanisms of Action
CLK inhibitors offer a differentiated therapeutic approach by modulating alternative RNA splicing, providing opportunities to overcome resistance mechanisms and enhance treatment outcomes in cancers driven by spliceosome dysfunction.

CDC-like Kinase (CLK) Inhibitors Market Analysis

The CDC-like Kinase (CLK) Inhibitors market represents an emerging segment within precision oncology focused on RNA splicing modulation. CLKs are dual-specificity kinases that regulate alternative pre-mRNA splicing through phosphorylation of serine/arginine-rich proteins, a biological process increasingly recognized as a major contributor to cancer development and progression. Although no CLK-targeted therapy has yet received FDA approval, multiple investigational agents have demonstrated encouraging anti-proliferative activity in preclinical and early clinical studies. According to DelveInsight, continued advances in RNA splicing biology, increasing investment in targeted oncology, expansion into multiple indications, and the maturation of the clinical pipeline are expected to support robust growth of the CLK Inhibitors market across the Seven Major Markets through 2036.

Get a Free sample for the CDC-like Kinase (CLK) Inhibitors Market Forecast, Target Population & Competitive Landscape Report:
https://www.delveinsight.com/sample-request/clk-inhibitors-market-forecast?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
CDC-like Kinase (CLK) Inhibitors Competitive Landscape

The CDC-like Kinase (CLK) Inhibitors therapeutic landscape is rapidly evolving as growing evidence highlights the critical role of RNA splicing dysregulation in cancer biology. CLK inhibitors target CLK1-CLK4, dual-specificity kinases responsible for phosphorylation of serine/arginine-rich (SR) proteins involved in pre-mRNA splicing. By disrupting aberrant RNA splicing, these therapies have the potential to inhibit tumor cell proliferation and survival across multiple hematological malignancies and solid tumors. Currently, no CLK-targeted therapies have received FDA approval, although several promising small-molecule candidates are progressing through clinical development.

Leading companies advancing the CLK inhibitor pipeline include Chordia Therapeutics, BlossomHill Therapeutics, Biosplice Therapeutics, Curis, and others developing first-in-class RNA splicing-targeted therapies.

Rogocekib (CTX-712): Chordia Therapeutics
Rogocekib (CTX-712) is a first-in-class, orally available pan-CLK inhibitor developed by Chordia Therapeutics. The therapy selectively inhibits CDC-like kinases and has demonstrated anti-tumor activity in preclinical models by inducing cancer cell death through disruption of RNA splicing. CTX-712 has successfully established proof-of-concept in a first-in-human Phase I clinical study conducted in Japan and is currently being evaluated in a Phase I/II trial involving patients with relapsed/refractory Acute Myeloid Leukemia (AML) and Higher-risk Myelodysplastic Syndrome (HR-MDS). The therapy has also received US FDA Orphan Drug Designation (ODD) for relapsed/refractory AML. In January 2026, Chordia Therapeutics announced publication of the final peer-reviewed Phase I clinical results of Rogocekib in Blood Advances.

BH-30236: BlossomHill Therapeutics
BH-30236 is a novel, orally available, macrocyclic ATP-competitive and highly selective CLK inhibitor being developed by BlossomHill Therapeutics. The therapy is designed to target dysregulated RNA splicing events responsible for tumor growth and disease progression. Preclinical studies have demonstrated encouraging activity in patient-derived AML cells, including those resistant to venetoclax. BH-30236 is currently being evaluated as both monotherapy and combination therapy with venetoclax in a first-in-human Phase I/Ib dose-escalation study involving adults with relapsed/refractory AML and Higher-risk Myelodysplastic Syndrome (HR-MDS). In March 2026, BlossomHill Therapeutics announced new preclinical data supporting continued advancement of the BH-30236 clinical program.

Lorecivivint (SM04690): Biosplice Therapeutics
Lorecivivint (SM04690) is a small-molecule injectable CLK inhibitor developed by Biosplice Therapeutics for the treatment of Knee Osteoarthritis. Administered once or twice annually through intra-articular injection, Lorecivivint has demonstrated improvements in pain, physical function, and medial joint space width across multiple clinical studies while maintaining a favorable safety profile. The therapy is currently in Phase III clinical development. In January 2026, Biosplice Therapeutics announced submission of a New Drug Application (NDA) to the US FDA for the treatment of knee osteoarthritis.

Emavusertib (CA-4948): Curis
Emavusertib (CA-4948) is one of the emerging investigational therapies included within the evolving CLK inhibitor competitive landscape. The therapy is being evaluated across oncology indications as part of the expanding RNA splicing-targeted therapeutic pipeline.

Cirtuvivint (SM08502): Biosplice Therapeutics
Cirtuvivint (SM08502) is another investigational small-molecule CLK inhibitor being developed by Biosplice Therapeutics for oncology applications. The therapy represents part of the company's expanding RNA splicing-targeted portfolio and is expected to strengthen the future competitive landscape.

Discover more about therapies expected to transform the CDC-like Kinase (CLK) Inhibitors market @ CDC-like Kinase (CLK) Inhibitors Treatment Landscape

Recent Developments in the CDC-like Kinase (CLK) Inhibitors Market

• In March 2026, BlossomHill Therapeutics announced new preclinical data supporting continued advancement of BH-30236, an oral CLK inhibitor being developed for hematologic malignancies.
• In January 2026, Chordia Therapeutics announced publication of the final peer-reviewed Phase I clinical trial results of Rogocekib (CTX-712) in Blood Advances.
• In January 2026, Biosplice Therapeutics announced submission of a New Drug Application (NDA) to the US FDA for Lorecivivint (SM04690) for the treatment of Knee Osteoarthritis.
• Rogocekib (CTX-712) continues to be evaluated in a Phase I/II clinical trial in patients with relapsed/refractory AML and Higher-risk Myelodysplastic Syndrome, following receipt of US FDA Orphan Drug Designation for relapsed/refractory AML.

What are CDC-like Kinase (CLK) Inhibitors?

CDC-like Kinase (CLK) inhibitors are small-molecule targeted therapies designed to inhibit CLK1, CLK2, CLK3, and CLK4, a family of dual-specificity kinases responsible for regulating alternative pre-mRNA splicing through phosphorylation of serine/arginine-rich proteins. Dysregulated RNA splicing has emerged as an important driver of tumor development, making CLK inhibition an attractive therapeutic strategy across hematological malignancies and solid tumors. Most CLK inhibitors are orally administered and are currently being evaluated for oncology indications, with additional exploratory research investigating potential applications beyond cancer.

CDC-like Kinase (CLK) Inhibitors Target Population Segmentation

The DelveInsight report evaluates the potential target population for CDC-like Kinase (CLK) inhibitors across the Seven Major Markets (7MM) during 2022-2036, including:
• Total Cases of Selected Indications
• Total Eligible Patient Pool for CLK Inhibitors
• Total Treatable Cases for CLK Inhibitors
• Acute Myeloid Leukemia (AML)
• Small Cell Lung Cancer (SCLC)
• Colorectal Cancer (CRC)
• Knee Osteoarthritis
• Other Selected Indications across the United States, EU4 and the United Kingdom, and Japan.

Download the report to explore target patient population trends, emerging therapies, competitive intelligence, and commercial opportunities in the CDC-like Kinase (CLK) Inhibitors market:
https://www.delveinsight.com/sample-request/clk-inhibitors-market-forecast?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the CDC-like Kinase (CLK) Inhibitors Market Report

• Study Period: 2022-2036
• Coverage: Seven Major Markets (7MM) - United States, Germany, France, Italy, Spain, the United Kingdom, and Japan
• Key Companies: Chordia Therapeutics, BlossomHill Therapeutics, Biosplice Therapeutics, Curis, and others
• Target Indications: Acute Myeloid Leukemia (AML), Small Cell Lung Cancer (SCLC), Colorectal Cancer (CRC), Knee Osteoarthritis, and others
• Emerging Therapies: Rogocekib (CTX-712), BH-30236, Lorecivivint (SM04690), Cirtuvivint (SM08502), Emavusertib (CA-4948), and others
• Target Population Analysis: Total cases, eligible patient pool, and treatable patient population across selected indications
• Market Insights: Historical and forecasted market size, therapy uptake, pricing trends, analogue assessment, competitive landscape, SWOT analysis, and market forecasts through 2036
• Market Access: Country-specific reimbursement and Health Technology Assessment (HTA) landscape across the 7MM
• Additional Coverage: Technology assessment, KOL perspectives, market dynamics, analyst views, and commercialization outlook.

To learn more about the CDC-like Kinase (CLK) Inhibitors market, target population, and emerging treatment landscape, visit:
https://www.delveinsight.com/sample-request/clk-inhibitors-market-forecast?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

• CDC-like Kinase (CLK) Inhibitors Market Report Introduction
• CDC-like Kinase (CLK) Inhibitors Market Executive Summary
• Key Events
• Epidemiology and Market Forecast Methodology
• CDC-like Kinase (CLK) Inhibitors Market Overview at a Glance
• CDC-like Kinase (CLK) Inhibitors Background and Overview
• Potential of CDC-like Kinase (CLK) Inhibitors in Different Indications
• Clinical Applications of CDC-like Kinase (CLK) Inhibitors
• CDC-like Kinase (CLK) Inhibitors Target Patient Pool
• Total Cases of Selected Indications in the 7MM
• Total Eligible Patient Pool in the 7MM
• Total Treatable Cases in Selected Indications
• Emerging CDC-like Kinase (CLK) Inhibitors
• Key Competitors
• Rogocekib (CTX-712): Chordia Therapeutics
• BH-30236: BlossomHill Therapeutics
• Lorecivivint (SM04690): Biosplice Therapeutics
• Cirtuvivint (SM08502): Biosplice Therapeutics
• Emavusertib (CA-4948): Curis
• CDC-like Kinase (CLK) Inhibitors Market Analysis
• Market Outlook
• Conjoint Analysis
• Key Market Forecast Assumptions
• Pricing Trends and Analogue Assessment
• Market Size Analysis (2022-2036)
• Market Size by Indication
• Market Size by Therapy
• SWOT Analysis
• Key Opinion Leader (KOL) Views
• Unmet Needs
• Market Access and Reimbursement
• Appendix

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.